Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 877 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Endocrine Clear all

Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Fulvestrant or an Aromatase Inhibitor (Physician Choice), LHRH Agonist; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Marietta, Georgia • Cleveland, Ohio • Tigard, Oregon

Conditions: Prostate Adenocarcinoma
Interventions: Radiation therapy; Radiation
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions: Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector; Combination Product
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 27
States / cities: Phoenix, Arizona • Palo Alto, California • Sacramento, California + 23 more

Conditions: Gestational Diabetes, Type 2 Diabetes
Interventions: Glucose tolerance test (2 hour), Active Comparator; Diagnostic Test · Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Breast Cancer
Interventions: leuprolide, letrozole, zoledronic acid; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 4
States / cities: Denver, Colorado • Boston, Massachusetts • Newton, Massachusetts

Conditions: Breast Cancer
Interventions: anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 1,939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 1454
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 888 more

Conditions: Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes, Morbid Obesity
Interventions: Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound; Drug · Diagnostic Test
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years to 25 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cushing's Syndrome
Interventions: mifepristone; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 15
States / cities: Birmingham, Alabama • Escondido, California • Stanford, California + 12 more

Conditions: Endocrine Disorder
Interventions: CardioFlux; Diagnostic Test
Lead sponsor: Genetesis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer With Bone Involvement, Bone Metastases in Subjects With Advanced Breast Cancer, ER-Positive HER2-Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Hormone-sensitive Metastatic Breast Cancer, Hormone-Sensitive Breast Cancer
Interventions: RYZ101, Standard of Care Endocrine Therapy; Drug
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: Not listed
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 25
States / cities: Phoenix, Arizona • Irvine, California • San Diego, California + 21 more

Conditions: Osteoporosis, Bone Diseases, Endocrine, Hyperparathyroidism
Interventions: Parathyroid Hormone (1-34); Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 24 Years to 35 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
Interventions: Onapristone, Fulvestrant; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Diabetes Mellitus Type 2, Social Determinants of Health (SDOH), Hospital Readmission
Interventions: REDDCAT2 Post-Discharge Navigation, Treatment as Usual (TAU); Behavioral · Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Adrenal Insufficiency, Critical Illness
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 1 Day to 18 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV, Depression, Cannabis Use Disorder, Stress, Pain
Interventions: Yale Pain Stress Task (YPST); Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 68 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes
Interventions: Technology-Assisted Case Management; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 120 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Breast Cancer
Interventions: high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Rochester, Minnesota • Omaha, Nebraska

Conditions: Pancreatic Cancer
Interventions: Synthetic Human Secretin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Stress, Pain
Interventions: Pray Until Something Happens (PUSH), Self-monitoring; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, D Vitamin, Dual X-ray Absorptiometry, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor: University of Rochester; Other
Eligibility: 50 Years and older · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 51
States / cities: Newark, Delaware • Danville, Illinois • Decatur, Illinois + 39 more

Conditions: Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia
Interventions: Insulin protocol; Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Psychotherapy, Therapeutic Alliance, Psychological
Interventions: Self-Monitoring, Individual Psychotherapy; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 520 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer
Interventions: Benralizumab, fulvestrant or AIs) and PI3K inhibition (alpelisib); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more

Conditions: Diabetes Mellitus
Interventions: Not listed
Lead sponsor: DexCom, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Escondido, California • Idaho Falls, Idaho • Boston, Massachusetts + 1 more

Search by objective public record fields.

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

Preventing T2DM After GDM With Immediate Postpartum Screening

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

GLP_1 RA Ultrasound Study

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Magnetocardiography Endocrine Registry

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

7 Day Continuous Parathyroid Hormone IV Infusion

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Re-Engineered Discharge for Diabetes Care Transitions

Pilot Study Assessing Oxidative Stress in Children

Stress and Pain in People Living With HIV

Technology-assisted Case Management in Adults With Type 2 Diabetes

Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

The Feasibility of the Pray Until Something Happens (PUSH) Intervention-OUTPATIENT

Vitamin D for Prostate Endocrine Therapy

Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients

Self-monitoring and Reflection's Impact on Psychotherapy Outcomes: A Trial Protocol.

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator